Study on efficacy and safety of high molecular weight hyaluronic acid "Hylan G-F 20" for patients with osteoarthritis of the hip
- Conditions
- Osteoarthritis of the hip
- Registration Number
- JPRN-UMIN000018000
- Lead Sponsor
- Department of Orthopaedic Surgery, Tokyo Medical and Dental University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
Exclusion criteria of the patients are as follows. (1)Patients lacking ability to agree or ability to express agreement for participation appropriately in this study. (2)Pregnancy or its possibility. (3)Patients suckling child. (4)Patients with hypersensitivity for the ingredient of this medicine, hyaluronic acid, avian protein, feather, or egg. (5)Patients with stagnation of venous blood or lymph fluid in lower limbs on injection side. (6)Patients with a serious liver damage or its medical history. (7)Patients with skin disease or with infection on the injection part. (8)Patients with serious complications (heart disorder, renal disease, a malignant tumor, or compromised host such as immunodeficiency). (9)Patients judged inadequate by the attending doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Physical findings and patient-based subjective assessment right after, 4, 8, and 12 weeks after intra-articular injection of hyaluronic acid
- Secondary Outcome Measures
Name Time Method Incidence of adverse events